Annual Revenue Growth (Last Twelve Months): Burning Rock Biotech Ltd (BNR)

Burning Rock Biotech (BNR) faces regulatory risks in the PRC despite the high transparency of audits. The trailing twelve months (TTM) annual growth in operating sales revenue reflects revenue dynamics, where the -3.60 mark characterizes this parameter. Patent protection and access to biodata strengthen the company's position, yet government pressure on the cost of medical services forces the business to provide significant discounts to clinics.
Summary analytical data breakdowns for Burning Rock Biotech Ltd. (BNR)

This indicator measures the dynamics of total revenue over a rolling twelve-month period relative to the previous year. For Burning Rock Biotech (BNR), this metric reveals the impact of geopolitical restrictions on biotechnology exports and data exchange. By analyzing the annual sales growth rate over a 12-month window, an investor distinguishes random spikes from a systemic trend. A decline in growth rates signals a risk of business stagnation, while a stable trajectory confirms capital resilience.